Previous Chief Executive Officer · Starling Oncology, Inc. (STLN)

Brad Hively

A named executive officer of Starling Oncology in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,215,190

Salary $293,500Stock awards $167,638

FY2022: $6,629,723

1st of 4 named executive officers at Starling Oncology by FY2023 total.

4 named officers on file for Starling Oncology, FY2023

Brad Hively’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Starling Oncology’s whole pay program stands against its peers

  • Starling Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on STLN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 2, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Brad Hively’s full pay file as a PDF — free

More than this page: up to 10 years of Brad’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Brad Hively compensation by year

Starling Oncology Summary Compensation Table · all 4 fiscal years held
In US dollars, as Starling Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023
Salary$400,000$430,768$579,208$293,500
Bonus$11,228$49,987$0$0
Stock awards$0$2,614,116$962,533$167,638
Option awards$0$8,396,264$4,885,594$202,636
Non-equity incentive$188,772$132,800$190,188$0
Pension and deferred compensation$0$0$0$0
All other$11,400$11,600$12,200$551,416
Total$611,400$11,635,536$6,629,723$1,215,190

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Starling Oncology, Inc. DEF 14A filed May 2, 2024, accession 0001193125-24-129457, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Starling Oncology, Inc. filed document, accession 0001193125-24-129457. Every figure is read from that document and cited to the page and table it appears in. Filed May 2, 2024.

$611K
$11.6M
$6.6M
$1.2M
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU212,070$432,623—
RSU168,512$343,764—
RSU141,380$288,415—
RSU77,602$158,308—
RSU54,235$110,639—
RSU42,652$87,010—
Option251,771—$0.85
Option275,282—$7.09
Option393,891—$1.87
Option421,280—$0.48

Per the Outstanding Equity Awards at Fiscal Year-End table in Starling Oncology, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

26 Form 4 lines since the FY2023 proxy (filed May 2, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-21Sale10b5-1298,853$6.51411,976
2026-07-27Grant or award—27,108$0.00710,829
2025-12-15Sale—13,333$3.77683,721
2025-11-20Grant or award—32,407$0.00697,054
2025-11-20Grant or award—41,667$0.00664,647
2025-08-19Sale—20,221$4.06622,980
2025-06-03Exercise or conversion—684,528$0.851,396,561
2025-06-03Exercise or conversion—105,320$0.481,501,881

The 8 most recent of 26 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Starling Oncology’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Brad Hively · this pagePrevious Chief Executive Officer$1,215,190
Daniel VirnichChief Executive Officer$808,129
Mihir ShahChief Financial Officer$801,743
Yale PodnosChief Medical Officer$591,284

Board service

Starling Oncology board · FY2021–FY2025
Director compensation in US dollars, as Starling Oncology reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$75,000$240,000—$0$315,000
FY2024$75,000$6,820—$0$81,820
FY2023$39,167$86,584—$0$125,751
FY2021—————

Each year as the company reported it in Starling Oncology's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Starling Oncology pays directors a $75,000 cash retainer and $125,000 in RSUs. As stated in Starling Oncology's FY2025 proxy.

Committees

Compliance Committee

The full Starling Oncology compensation record

free company brief

This page is one person within Starling Oncology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Starling Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Brad Hively's compensation dossier · One-time report. No refunds.